Table 4.
Prevalence and risk of STIs and cervical neoplasia by HIV status.
| STD by HIV | HIV (−) | HIV (+) | Adjusted* OR | 95% Cl | P | ||
|---|---|---|---|---|---|---|---|
| N = 226 | N = 30 | ||||||
| n | % | n | % | ||||
| Gonococcal infection | 27 | 12 | 6 | 20 | 1.9 | (0.7; 5.5) | .219 |
| Syphilis (RPR & IgG) | 26 | 12 | 5 | 17 | 1.6 | (0.5; 4.5) | .408 |
| HPV DNA | 83 | 37 | 14 | 47 | 1.6 | (0.7; 3.5) | .262 |
| HSV-2 antibodies | 185 | 82 | 27 | 90 | 2.1 | (0.6; 7.6) | .259 |
| Chlamydia trachomatis DNA | 14 | 6 | 5 | 17 | 3.1 | (1.0; 9.6) | .051 |
| Trichomona vaginalis | 67 | 30 | 9 | 30 | 1.0 | (0.4; 2.4) | .966 |
| HBsAg anribodies | 19 | 8 | 1 | 3 | 0.4 | (0.1; 3.0) | .359 |
| Anti-HBc antibodies | 137 | 61 | 22 | 73 | 1.8 | (0.8; 4.3) | .172 |
| Any treatable STI** | 107 | 47 | 18 | 60 | 1.7 | (0.8; 3.8) | .190 |
| Cervical neoplasia | 23 | 10 | 6 | 20 | 2.5 | (0.9; 7.0) | .088 |
*Adjusted by age and ethnic group.
**Any treatable STI: syphilis (RPR confirmed by IgG), gonococcal infection, trichomona vaginalis or chlamydia trachomatis.